

Cover Story
Guest Editorial
The initial reports of the near-miraculous benefits of CAR-T in pediatric acute lymphoblastic leukemia generated tremendous excitement—there was a Lazarus-like quality to these stories.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research
- Anthony Letai sworn in as 18th NCI director
- U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs - Former NCI official’s nonprofit seeks to tell the stories of cancer patients
Patient Action for Cancer Research aims to show impact of federal research - Sakaguchi, Ramsdell, Rudensky win Crafoord Prize for discoveries in immune regulation
- The evolution of cellular immunotherapy: From transplant to CAR T cells